

4121-171

SECTION II
AMENDMENTS TO THE CLAIMS

RECEIVED
CENTRAL FAX CENTER
AUG 02 2007

Please cancel claims 5, 6, 9, 16, and 17 without prejudice.
Please amend claims 1, 3, 4, 7, and 8 as set forth below.
Please add new claims 20-29 presented below.

Complete Listing of the Claims

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

1. (Currently amended) A diagnostic conjugate for tumor imaging having the structure:
comprising the following components:
(a) ~~—~~ a transmembrane module (TPU); ~~—~~ (b) ~~—~~ an address module (AS); and ~~—~~ (c) ~~—~~ a signalling module (SM), wherein the transmembrane module is a transport peptide capable of penetrating the plasma membrane; the address module is a peptide nucleic acid (PNA) which hybridizes with a mRNA, the expression or mis-expression of which is associated with a tumor disease; and the signaling module is selected from the group consisting of Gadolinium, iron and fluorine.
2. (Original) The diagnostic conjugate of claim 1, wherein the transmembrane module (TPU) is a human transmembrane peptide.
3. (Currently amended) The diagnostic conjugate of claim 2, wherein the transmembrane module (TPU) comprises the amino acid sequence KMTRQTWVHRIKHKC (SEQ ID NO: 2); MTRQTFVHRIKHKC (SEQ ID NO: 3) or KHKIRHWFTQRTMC (SEQ ID NO: 4).
4. (Currently amended) The diagnostic conjugate of claim 1, wherein the peptide nucleic acid (PNA) of the address module (AS) is an antisense peptide nucleic acid (PNA).
- 5.-6. (Cancelled)
7. (Currently amended) The diagnostic conjugate of claim 16, wherein the ~~antisense~~ peptide nucleic acid (PNA) is capable of hybridizing with c-myc-, c-ras-, her-, sst1 or sst2-mRNA.

4121-171

8. (Currently amended) The diagnostic conjugate of claim 7, wherein the ~~antisense~~ peptide nucleic acid (PNA) comprises the sequence H₂N-ATGCCCCTCAACGTTAGCTT-COOH (SEQ ID NO: 5).
9. (Cancelled)
10. (Previously presented) The diagnostic conjugate of claim 1, wherein the transmembrane module (TPU) is coupled to the address module (AS) via a covalently cleavable spacer I and/or the address module (AS) is coupled to the signalling module (SM) or a compound trapping the signalling module (SM) via a covalently non-cleavable spacer II.
11. (Original) The diagnostic conjugate of claim 10, wherein spacer I comprises a cleavable disulfide bridge.
12. (Original) The diagnostic conjugate of claim 10, wherein spacer I and/or spacer II comprises polylysine or polyglycine.
13. (Previously presented) The diagnostic conjugate of claim 12, wherein spacer II carries an FITC-label.
14. (Previously presented) The diagnostic conjugate of claim 1 having the following structure: transmembrane module (TPU) - spacer I comprising a cleavable disulfide bridge - address module (AS) - spacer II - signalling module (SM) or compound trapping the signalling module (SM).
15. (Previously presented) A diagnostic composition containing a diagnostic conjugate of claim 1.
- 16.-17. (Cancelled)
18. (Previously presented) The diagnostic conjugate of claim 9, wherein the transmembrane module (TPU) is coupled to the address module (AS) via a covalently cleavable spacer I and/or the address module (AS) is coupled to the signalling module (SM) or a compound trapping the signalling module (SM) via a covalently non-cleavable spacer

4121-171

19. (Previously presented) A diagnostic composition containing a diagnostic conjugate of claim 14.
20. (New) A diagnostic conjugate for tumor imaging having the structure:
- transmembrane module (TPU)-address module (AS)-signalling module (SM),
- wherein the transmembrane module (TPU) is a transport peptide which can penetrate the plasma membrane selected from the group consisting of penetratin and transportan; the address module (AS) is a peptide nucleic acid (PNA) which hybridizes with a mRNA of a gene selected from the group consisting of c-myc-, c-ras-, henn-1 or henn-2 and the signalling module (SM) is selected from the group consisting of Gadolinium, iron and fluorine.
21. (New) The diagnostic conjugate of claim 20, wherein the transport peptide is a human transport peptide.
22. (New) The diagnostic conjugate of claim 20, wherein the transport peptide comprises the amino acid sequence KMTRQTWWHRIKHKC (SEQ ID NO: 2); MTRQTFWHRIKHKC (SEQ ID NO: 3) or KHKIRHWFTQRTMC (SEQ ID NO: 4).
23. (New) The diagnostic conjugate of claim 20, wherein the peptide nucleic acid (PNA) comprises the sequence H₂N-ATGCCCCCTCAACGTTAGCTT-COOH (SEQ ID NO: 5).
24. (New) The diagnostic conjugate of claim 20, wherein the transmembrane module (TPU) is coupled to the address module (AS) via a covalently cleavable spacer I and/or the address module (AS) is coupled to the signalling module (SM) or a compound trapping the signalling module (SM) via a covalently non-cleavable spacer II.
25. (New) The diagnostic conjugate of claim 24, wherein spacer I comprises a cleavable disulfide bridge.
26. (New) The diagnostic conjugate of claim 24, wherein spacer I and/or spacer II comprises polylysine or polyglycine.
27. (New) The diagnostic conjugate of claim 25, wherein spacer II carries an FITC-label.

4121-171

28. (New) The diagnostic conjugate of claim 20 having the following structure: transmembrane module (TPU) - spacer I comprising a cleavable disulfide bridge - address module (AS) - spacer II - signalling module (SM) or compound trapping the signalling module (SM).
29. (New) A diagnostic composition containing a diagnostic conjugate of claim 20 and pharmaceutically acceptable carrier.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK